Osmind is pleased to announce Dr. Robert M. Berman, M.D., as our new Strategic Advisor.

‍

Dr. Berman's distinguished career spans academia and biopharma with a focus on advancing mental health care and neuropsychiatry. As Co-founder and inaugural Chief Medical Officer of Biohaven Pharmaceuticals, he spearheaded the development of innovative therapies for neurological and neuropsychiatric disorders. His leadership at Bristol-Myers Squibb and Pfizer advanced psychiatric and neurological therapeutics, including leading the clinical development program for aripiprazole as an augmentation agent for depression.

‍

Throughout his career, Dr. Berman has pursued a clear vision: to address unmet medical needs and improve treatments for patients with neuropsychiatric disorders.

‍

Dr. Berman's research has significantly impacted the field, particularly his work on the mechanism of action of antidepressants and novel treatments such as ketamine. He has made substantial contributions to psychiatry and neuroscience, including the first study of intravenous ketamine in patients with depression (Berman et al., 2000) which gave such hope to patients and clinicians. We finally had a novel mechanism of action for depression that acted on the order of hours to days rather than weeks to months.

‍

Dr. Berman is an adjunct professor of psychiatry at the Yale School of Medicine and currently serves on the boards of Osmol Therapeutics, Gilgamesh Pharmaceuticals, and Manifest Technologies. He is also an advisor for Freedom Biosciences, MindImmune Therapeutics, and Biohaven Pharmaceuticals. 

‍

"My work has always been driven by the urgent need to develop better therapies, with the potential for substantially advanced efficacy," says Dr. Berman. "By translating cutting-edge research into innovative clinical approaches, we can significantly improve outcomes for patients with neuropsychiatric disorders."

‍

Advancing Neuropsychiatry with Osmind

‍

Osmind supports partners from pharmaceutical companies to clinical-stage biotechs, offering services from real-world evidence generation to commercial launch support. 

‍

Dr. Berman's expertise in neuroscience research will guide Osmind's research initiatives, ensuring we remain at the forefront of developing breakthrough treatments for neuropsychiatric disorders.

‍

"We're at a critical juncture in neuropsychiatry. Leveraging real-world evidence can accelerate breakthrough treatment development. Osmind’s platform offers an extremely large source of longitudinal data. I'm excited to work with Osmind to develop more effective, personalized treatments for mental health conditions."

‍

For more information on our work in neuropsychiatry research and treatment, visit Osmind.org/life-sciences.